IP Library Granted Patent US 7,790,773
Granted Patent B2
US 7,790,773 · App. 10/793,857 · Granted Sep 7, 2010

Carba-sugar amine derivative and glycolipid metabolic disorder treating agent containing the same as active ingredient

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,790,773
App. No.
10/793,857
Granted
Sep 7, 2010
Kind
B2
Abstract

A carba-sugar amine derivative represented by the following formula (1) or (2) is used as the active ingredient of a β-galactosidase inhibitor or a glycolipid metabolic disorder treating agent. Wherein each of R 1 and R 2 independently represents H, an alkyl group, an acyl group, an aryl group or an aralkyl group, with the proviso that both are not H at the same time, and each of R 3 , R 4 , R 5 and R 6 independently represents a hydroxyl group or hydroxyl group having a substituent. Also, R 7 represents an alkyl group, and each of R 8 , R 9 , R 10 and R 11 independently represents a hydroxyl group or a hydroxyl group having a substituent.

Claims (7)

1. A carba-sugar amine compound represented by the following formula (1):

2. An agent for treating a glycolipid metabolic disorder selected from the group consisting of G m1 gangliosidosis, Morquio-B disease and Krabbe's disease, which comprises the carba-sugar amine compound according to claim 1 as an active ingredient.

3. The agent for treating a glycolipid metabolic disorder according to claim 2 , which is a preparation for oral administration.

4. A method for stabilizing β-galactosidase comprising administering to a subject in need thereof an effective amount of a composition comprising the carba-sugar amine compound according to claim 1 as an active ingredient.

5. A method for treating a glycolipid metabolic disorder selected from the group consisting of G m1 gangliosidosis, Morquio-B disease, and Krabbe's disease, comprising administering to a subject in need thereof an effective amount of the carba-sugar amine compound according to claim 1 .

6. The method according to claim 5 , wherein the carba-sugar amine compound is orally administered.

7. A method for regenerating the activity of β-galactosidase reduced or lost due to a mutation in the living body, comprising administering to a subject in need thereof an effective amount of the carba-sugar amine compound according to claim 1 .

Assignments (2)
CORPORATE ADDRESS CHANGE Recorded Sep 27, 2005
From: SEIKAGAKU KOGYO KABUSHIKI KAISH/AKA/SEIKAGAKU CORPORATION
To: SEIKAGAKU KOGYO KABUSHIKI KAISH/AKA/SEIKAGAKU CORPORATION
Reel/Frame 016843/0715 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2004
From: OGAWA, SEIICHIRO; SUZUKI, YOSHIYUKI; NANBA, EIJI; MATSUDA, JUNICHIRO; OHNO, KOUSAKU
To: SEIKAGAKU CORPORATION
Reel/Frame 015566/0267 →